Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai ChemPartner Aids Agios’ Cancer Research Breakthrough

publication date: Dec 9, 2009
Shanghai ChemPartner, one of ShangPharma’s several subsidiaries, said its scientists contributed to the breakthrough cancer research announced by Agios Pharmaceuticals, with whom ChemPartner has an ongoing relationship. In the November 22 online issue of Nature, Agios scientists published an article entitled "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)." Their research, at least partly carried out at ChemPartner, showed the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene, revealing new possibilities for novel cancer treatments. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here